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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYEmbryonic stem cells (ESCs) have adopted an accelerated cell-cycle programwith shortened gap phases and precocious expression of cell-
cycle regulatory proteins, including cyclins and cyclin-dependent kinases (CDKs).We examined the effect of CDK inhibition on the path-
ways regulating proliferation and survival of ESCs.We found that inhibiting cyclin-dependent kinase 1 (CDK1) leads to activation of the
DNA damage response, nuclear p53 stabilization, activation of a subset of p53 target genes including NOXA, and negative regulation of
the anti-apoptotic proteinMCL1 in human andmouse ESCs, but not differentiated cells. We demonstrate thatMCL1 is highly expressed
in ESCs and loss of MCL1 leads to ESC death. Finally, we show that clinically relevant CDK1 inhibitors prevent formation of ESC-derived
tumors and induce necrosis in established ESC-derived tumors. Our data demonstrate that ES cells are uniquely sensitive to CDK1 inhi-
bition via a p53/NOXA/MCL1 pathway.INTRODUCTION
Embryonic stem cells (ESCs) are derived from the inner
cell mass of the blastocyst, during a stage of development
defined by rapid cell division rates. Mouse and human
ESCs grown in culture retain the rapid proliferation
observed in early embryonic cells, exhibiting an acceler-
ated cell-cycle program characterized by a shortened G1
phase and differentially regulated cell-cycle checkpoints
(Orford and Scadden, 2008). When ESCs differentiate,
their cell-cycle structure changes to incorporate a longer
G1 phase and slower proliferation rates. Whether their
unique cell-cycle program alters ESC dependency on
cell-cycle regulatory proteins has not been previously
established.
Cell-cycle adaptations that account for the altered ESC
cell-cycle structure were first identified in mouse ESCs
(mESCs) (Ballabeni et al., 2011; Orford and Scadden,
2008). Cyclin/CDK complexes represent the key enzymes
that regulate orderly progression through the mammalian
cell cycle. In somatic cells, cyclin abundance fluctuates
throughout the cell cycle, in part due to degradation by
the anaphase-promoting complex/cyclosome (APC/C) at
the end of mitosis (reviewed in Morgan, 2007). In mESCs,
however, APC/C activity is attenuated due to high levels
of EMI1 (early mitotic inhibitor 1), resulting in reduced
fluctuation of cyclin expression (Ballabeni et al., 2011).374 Stem Cell Reports j Vol. 4 j 374–389 j March 10, 2015 j ª2015 The AuthAdditionally, mESCs express higher levels of cyclins E, A,
and B compared to somatic cells (Stead et al., 2002) and
do not appreciably express the endogenous CDK inhi-
bitors, including INK family members (p15, p16, and
p19) and CIP/KIP family members (p21 and p27) (Sabapa-
thy et al., 1997).
Cell-cycle adaptations in human ESCs (hESCs) are less
defined. In contrast to mESCs, hESCs exhibit significant
fluctuation of cyclin expression in a cell-cycle-dependent
manner (Neganova et al., 2009), indicating differences in
the regulation of key cell-cycle proteins between the two
cell types. Similar to mESCs however, hESCs exhibit
high expression of cyclins A and E as well as undetectable
expression of p21 and p27 (Becker et al., 2006). In both
cell types, elevated cyclin activity combined with lack of
endogenous CDK inhibitors results in increased activity
of CDK1 and 2 and diminished G1 and G2 cell-cycle
phases.
It remains unknown if the altered cell-cycle program
employed by mouse and human ESCs results in unique
dependencies on individual cell-cycle proteins. Further-
more, whether there is a connection between the ES
cell-cycle program and the cell-death pathways em-
ployed by ESCs has not been explored. Acute inhibition
of CDK1 or CDK2 in proliferating somatic cells generally
results in reversible arrest of the cell cycle without signif-
icant cell death (Gray et al., 1998; Horiuchi et al., 2012;ors
van den Heuvel and Harlow, 1993). Here, we use small
interfering RNA (siRNA) knockdown and small molecule
CDK inhibitors to identify critical pathways regulating
cell proliferation and survival in mouse and human
ESCs.RESULTS
Depletion of CDK1, Cyclin A, or Cyclins B1/B2 Causes
Apoptosis in Mouse Embryonic Stem Cells
To determine if mESCs exhibit unique dependencies on
cell-cycle regulatory proteins, we transiently transfected
small interfering RNAs (siRNAs) to systematically deplete
CDKs 1 and 2, and cyclins D, E1/E2, A2, and B1/B2. 72 hr
post-transfection, western blot analysis revealed effective
and specific siRNA-mediated knockdown of these proteins
(Figure 1A).
We evaluated the effects of CDK/cyclin knockdown on
the mES cell cycle using propidium iodide (PI) to stain for
DNA content. Knockdown of CDK2, cyclin D, or cyclins
E1/E2 had little effect on cell-cycle profiles (Figure 1B),
consistent with existing reports in somatic cells andmouse
knockout models (Barrie`re et al., 2007; Li et al., 2012; Tetsu
and McCormick, 2003) and did not significantly affect
mESC viability, as measured using sub-2N DNA content
as a marker of cell fragmentation and death (Figures 1B
and 1C). Western blotting showed no evidence of poly
(ADP-ribose) polymerase (PARP) cleavage, a marker of cas-
pase-dependent apoptosis (Figure 1D), and microscopic
evaluation of mESC morphology (Figure 1B) revealed find-
ings consistent with viable cells.
In contrast, knockdown of cyclin A resulted in an in-
creased percentage of live cells in the S and G2/M phases,
and a reduced percentage of live cells in G1 (Figure 1B).
This is similar to findings reported in cyclin-A-deficient
ES cells (Kalaszczynska et al., 2009). Knockdown of cyclin
A also resulted in an approximate 20% increase in the per-
centage of fragmented cells (Figure 1C) and a small increase
in PARP cleavage (Figure 1D), compared to control siRNA.
Knockdown of CDK1, or cyclins B1/B2, resulted in more
pronounced cell fragmentation (approximately 30% and
55%, respectively) (Figures 1B and 1C) and PARP cleavage
(Figure 1D). Thus, depletion of CDK1 or its cyclin binding
partners (cyclins A2 and B1/B2)—but not other CDKs and
cyclins—induces cell death in mESCs.
Previous reports have shown that CDK1 inhibition in-
duces differentiation in some types of pluripotent cells
(Ullah et al., 2008). We found no evidence of differentia-
tion of mESCs after siRNA-mediated knockdown of any
of the CDKs or cyclins (Figure S1). This is consistent with
findings that elongation of themES cell cycle is compatible
with pluripotency (Li et al., 2012).Stem CSmall-Molecule-Mediated Inhibition of CDK1 Induces
Apoptosis in mESCs
A more clinically relevant method to disrupt CDK activity
involves small molecule inhibitors that block kinase activ-
ity at the ATP-binding site.We asked if smallmolecule inhi-
bition of CDK1 would result in similar effects as those seen
after siRNA-mediated knockdown. mESCs were treated
with a CDK2 inhibitor, CVT-313 (5 mM), and two CDK1
inhibitors, purvalanol A (10 mM) and Ro-3306 (9 mM). In-
hibitors were used at concentrations shown to effectively
target the activity of the kinases in prior studies (Brooks
et al., 1997; Goga et al., 2007; Gray et al., 1998; Vassilev
et al., 2006). Similar to CDK2 knockdown, treatment with
CDK2 inhibitor CVT-313 had no effect on sub2n DNA con-
tent (Figures 2A and 2B). In contrast, CDK1 inhibitors pur-
valanol A and Ro-3306 caused cell-cycle arrest at G2/M and
significant sub-2n levels (approximately 45% and 35%,
respectively, compared to a DMSO-treated control) within
24 hr of treatment (Figures 2A and 2B). As purvalanol A
produced a stronger effect than Ro-3306 treatment, we
exclusively used purvalanol A in subsequent experiments.
Thus, similar to siRNAmediated CDK1 and cyclin B knock-
down, small molecule inhibitors of CDK1 elicit cell death
in mESCs.
Differentiated mESCs Are Resistant to CDK1
Inhibition
We induced mESCs to differentiate by removing leukemia
inhibitory factor (LIF) from the media and adding a low
dose of all-trans retinoic acid (RA). After 4 days of RA
treatment, mRNA levels of the pluripotency marker, Oct4,
were reduced over 100-fold (Figure S2A). Additionally,
OCT4 and a second pluripotency marker, Nanog, showed
a markedly reduced expression by immunofluorescence
(Figure S2B). Cell-cycle analysis of differentiated mES cells
(mES-diff) showed that 46% of cells were in S or G2/M
phases (28% in S and 18% in G2/M) indicating that these
cells are actively proliferating (Figure 2C). mES-diff cells
treated with purvalanol A underwent a G2/M arrest, sug-
gesting that CDK1 was being targeted and the cells were
actively cycling prior to the G2/M block (Figure 2C). In
contrast to undifferentiated cells, mES-diff cells did not un-
dergo cell death (Figure 2C). To confirm these results, we as-
sessed levels of apoptosis using a nucleic acid dye exclusion
viability assay and western blotting for PARP cleavage to
compare the effect of purvalanol A treatment on mES-diff
cells and a second differentiated cell type, mouse embry-
onic fibroblasts (MEFs), with mESCs and mouse-induced
pluripotent stem cells (miPSCs). mESCs andmiPSCs under-
went apoptosis, while the differentiated cell types did not
(Figures 2D and 2E). We generated dose-response curves,
using percentage cell death as a response, and found
that the relative half-maximal response (EC50) values forell Reports j Vol. 4 j 374–389 j March 10, 2015 j ª2015 The Authors 375
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Figure 1. siRNA Knockdown of CDK1 and CDK1 Cyclin Binding Partners Induces Apoptosis in mESCs
(A) Western blots of CDKs and cyclins protein levels 72 hr after siRNA transfection in mESCs. Ctrl, non-targeting control siRNA.
(B) Cell-cycle distribution 72 hr after siRNA transfection. Percentage of cells in each cell-cycle phase is indicated (mean ± SEM, n = 3
independent experiments). Morphology of cells after siRNA knockdown. Scale bars, 140 mm.
(C) sub2N DNA content from (B) (mean ± SEM, n = 3). Populations compared using Student’s t test, *p < 0.03.
(D) PARP cleavage by western blotting.
See also Figure S1.purvalanol A treatment against mES and mES-diff cells
differed significantly (Figure 2F). Collectively, these data
demonstrate that CDK1 inhibition selectively induces cell
death in pluripotent cells while sparing differentiated cells.
The determine if the difference in sensitivity to CDK1 in-
hibitors was due to the difference in proliferation rates be-
tween mESC and differentiated cells, we employed mESCs
that are deficient for DGCR8, which is essential for miRNA376 Stem Cell Reports j Vol. 4 j 374–389 j March 10, 2015 j ª2015 The Authbiogenesis (Wang et al., 2007). Dgcr8/ mESCs proliferate
slower, with a lengthened G1 phase compared to wild-type
mESCs, exhibiting a cell-cycle program similar to that of so-
matic cells (Wang et al., 2007). Despite a lower proliferative
index, Dgcr8/ mESCs underwent similar levels of cell
death as wild-type (WT) mESCs after CDK1 inhibitor
treatment (Figure 2D), suggesting that a difference in
cell-cycle dependency and/or cell-death pathways, ratherors
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Figure 2. Small Molecule Inhibition of CDK1 Kills mESCs but Not Differentiated Cells
(A) Effect of CDK inhibitors on mES cell-cycle distribution. Percentage of cells in each cell-cycle phase (mean ± SEM, n = three independent
experiments).
(B) sub2N DNA content from (A) (mean ± SEM, n = three independent experiments). Populations were compared using Student’s t test,
*p < 0.006.
(C) Effect of CDK inhibitors on differentiated mES (mES-diff) cell-cycle distribution. Percentage of cells in each cell-cycle phase (mean ±
SEM, n = 3 independent experiments).
(D) Cell viability after 24-hr treatment with DMSO or purvalanol A (purv) (10 mM), (mean ± SEM, n > 4 independent experiments).
Populations compared using a Student’s t test, **p < 0.005, *p = 0.018.
(E) Western blot for PARP cleavage after purvalanol A (purv) treatment for indicated times in hours; D, DMSO control.
(F) Dose-response curve for purvalanol A treatment of mES and mES-diff cells to determine (EC50) for each cell type (9.48 mM mES and
36.9 mMmES-Diff). Response measured as percentage maximum cell death for each cell type. p < 0.0001, determined by Fisher’s exact test.
See also Figure S2.then proliferation rates, contribute to the unique CDK1-in-
hibitor-induced cell death observed in pluripotent cells.
To identify cell-death pathways involved in CDK1-inhib-
itor-induced cell death, we utilized mES cells deficient inStem Cthe pro-apoptotic proteins, BCL2 homologous antagonist
killer (BAK) and Bcl2-associated protein X (BAX), two pro-
teins that are required for the intrinsic (mitochondrial)
apoptotic pathway (Wei et al., 2001). Bax/Bak/ mESCsell Reports j Vol. 4 j 374–389 j March 10, 2015 j ª2015 The Authors 377
were derived from previously described mice with a germ-
line deletion of Bak and a conditional allele of BaxFlox/, fol-
lowed by deletion of the Bax allele with Cre-recombinase
(E.S. Wang, N.A. Reyes, C. Melton, N.E.H., A.G., R.B., and
S.A.O., unpublished data) (Takeuchi et al., 2005). These
cells maintain expression of OCT4 and Nanog (Figure S2B)
but lack expression of BAX and BAK (Figure S2C). Bax/
Bak/ mESCs treated with purvalanol A underwent a
G2/M arrest, suggesting that purvalanol A effectively tar-
gets CDK1 in these cells (Figure S2D). In contrast to WT
mESCs, treatment of Bax/Bak/mESCs with purvalanol
A induced no cell death (Figure 2D) or PARP cleavage (Fig-
ure 2E). These data indicate that CDK1-inhibitor-induced
cell death in pluripotent cells occurs via the intrinsic
apoptotic pathway.
CDK1 Inhibitor Treatment Induces a DNA Damage
Response in Mouse ES, but Not Differentiated, Cells
CDKs regulate several components of the DNA damage
response pathway, and CDK1 activity is critical for repair
of double-stranded breaks (DSB) by homologous recombi-
nation (HR) (Falck et al., 2012; Johnson et al., 2011; Peter-
son et al., 2011). Additionally, it has been shown that ESCs
are highly sensitive to DNA damage, more frequently
undergoing apoptosis relative to differentiated cells (Liu
et al., 2013; Momcilovic et al., 2010). We hypothesized
that CDK1 inhibition triggers the DNA damage response
in mESCs. To address this hypothesis, we examined the ef-
fect of CDK1 inhibition on the phosphorylation of H2AX
in WT mES, Bax/ Bak/ mES, and mES-diff cells. Phos-
phorylation of H2AX at S139 (g-H2AX) occurs as an early
cellular response to DNA damage in mammalian cells. As
a positive control, cells were treated with doxorubicin, a
topoisomerase II inhibitor known to causeDSBs. Treatment
ofWTand Bax/ Bak/mESCswith purvalanol A resulted
in an increase in g-H2AX levels, comparable to treatment
with doxorubicin (Figure 3A). Because Bax/ Bak/
mESCs do not undergo CDK-inhibitor-induced cell death,
they are useful for identifying cellular effects occurring
upstream of cell death. Thus, our data suggest that CDK1
inhibition induces a DNA damage response upstream
of apoptosis in mESCs. Purvalanol A did not increase
g-H2AX levels in mES-diff cells, indicating that CDK-inhi-
bition-induced activation of the DNA damage response is
unique to pluripotent cells (Figure 3A). Consistent with
our western blot results, we observed an increase in the per-
centage of Bax/ Bak/ mESCs—but not differentiated
mESCs—containing g-H2AX foci after treatment with pur-
valanol A, by immunofluorescence (Figure 3B). Addition-
ally, we saw an increase in levels of phosphorylated ATM
(S1981), a marker of DSBs (Shiloh, 2003), in Bax/ Bak/
ESCs, but not mES-diff cells, after purvalanol A treatment
(Figure 3C). These data indicate that CDK1 inhibition acti-378 Stem Cell Reports j Vol. 4 j 374–389 j March 10, 2015 j ª2015 The Authvates the DNA damage response pathway in mES, but not
differentiated, cells.
CDK1-Inhibitor-Induced Cell Death in mES Cells
Is Mediated by p53
In response to DNA damage, the p53 tumor suppressor
protein initiates transcription of numerous target genes
involved in cell-cycle arrest and apoptosis (Vousden and
Lu, 2002). We asked if p53 mediates CDK1-inhibitor-
induced cell death in mESCs. Upon treatment with purva-
lanol A, mESCs deficient for p53 (Sabapathy et al., 1997)
underwent a G2/M arrest, indicating that CDK1 was effec-
tively inhibited (Figure 4A). Cell viability assays, however,
revealed that p53/mESCswere significantly less sensitive
to CDK1 inhibition relative toWTmESCs, with nearly 80%
of p53/ mESCs versus 40% of WT mESCs remaining
viable after treatment with purvalanol A (Figure 4B).
Consistent with this finding, western blot analysis revealed
PARP cleavage in WT, but not p53-deficient, mESCs (Fig-
ure 4C), suggesting that p53 mediates CDK1-inhibitor-
induced cell death in mESCs.
p53 activity is regulated at multiple levels, including pro-
tein stability and subcellular localization. Phosphorylation
of serine 18 (serine 15 in human) of p53 by ATMduring the
DNA damage response inhibits degradation of p53, thus
increasing p53 stability (Canman et al., 1998). We exam-
ined total p53 protein and phospho-serine 18 (S18) levels
after CDK inhibitor treatment in WT mESCs, Bax/
Bak/ mESCs, and mES-diff cells, using doxorubicin-
treated cells as a positive control. Purvalanol A treatment
increased p53 levels in WT mESCs and Bax/ Bak/
mESCs within 4 hr of treatment, comparable to treatment
with doxorubicin, which was accompanied by phosphory-
lation of S18 (Figure 4D). The levels of total and phosphor-
ylated p53 in mES-diff cells did not increase after purvala-
nol A treatment (Figure 4D), indicating that induction of
p53 protein levels after CDK1 inhibition is unique to
mESCs. We observed a similar increase in p53 levels after
siRNA knockdown of CDK1 and cyclins A or B1 and B2 in
mESCs, but not siRNA knockdown of cyclins D, E1/E2, or
CDK2 (Figure 4E), suggesting that induction of p53 is due
to CDK1 inhibition rather then an off-target effect of pur-
valanol A.
Phosphorylation of S18 by ATM inhibits the nuclear
export of p53 by masking a nuclear export signal (Zhang
and Xiong, 2001). To determine the localization of p53
in mESCs after CDK1 inhibitor treatment, we isolated
cytosolic and nuclear fractions and analyzed p53 protein
expression via western blot. Purvalanol A induced
localization of p53 within the nuclear fraction of mESCs
(Figure 4F). These data indicate that p53 is stabilized in
the nucleus in response to CDK1 inhibitor treatment in
mESCs.ors
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Figure 3. Inhibition of CDK1 Induces the DNA Damage Response in ES but Not Differentiated Cells
(A) Western blot for g-H2AX.
(B and C) Detection of g-H2AX foci (B) or phosphorylated ATM (S1981) (pATM) (C) by immunofluorescence in Bax/Bak/ mESCs and
differentiated mES (mES-diff). DAPI (blue) indicates cell nuclei. Cells were treated with DMSO as a negative control, 1 mM doxorubicin
(doxo) as a positive control, or 10 mM purvalanol A (purv) for 8 hr. Scale bars, 20 mm. Histograms represent mean ± SEM percentage of cells
expressing g-H2AX foci (B) or pATM (C), n = 4 independent experiments. Populations compared using a Student’s t test *p < 0.05; NS, not
significant.CDK1 Inhibition Induces Expression of BCL2 Family
Member NOXA and Depletes MCL1 to Induce Cell
Death in mESCs
To identify the pathways that are activated downstream of
p53 after CDK1 inhibitor treatment, we used a quantitative
PCR-based array to examinemRNA expression levels of p53
transcriptional targets in mES and mES-diff cells, after 8 hr
of purvalanol A treatment. At 8 hr, p53 activation occurs
(Figure 4D), but minimal cell death, as measured by PARPStem Ccleavage, is observed (Figure 4C). Surprisingly, many p53
transcriptional targets involved in apoptosis—including
Bax and Bbc3 (PUMA)—were not significantly altered
upon purvalanol A treatment of mESCs (Figure 5A). How-
ever, we did observe a significant increase in four estab-
lished p53 targets, Pmaip1 (NOXA), Rb, Trp73 (TP73), and
Zmat3 (WIG1) (Figure 5A). Consistent with our observa-
tions that p53 activity is not induced in mES-diff cells
following CDK1 inhibitor treatment, we did not observeell Reports j Vol. 4 j 374–389 j March 10, 2015 j ª2015 The Authors 379
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Figure 4. CDK1-Inhibitor-Induced Cell Death in mESCs Is
Mediated by p53
(A) Effect of purvalanol A on p53/ mESC cycle distribution.
Percentages of cells in each cell-cycle phase (mean ± SEM, n = 3
independent experiments).
(B) Cell viability after 24 hr of treatment, 10 mM purvalanol A,
normalized to DMSO-treated controls (mean ± SEM n = 5 indepen-
dent experiments). Populations compared using a Student’s t test
*p = 0.004.
380 Stem Cell Reports j Vol. 4 j 374–389 j March 10, 2015 j ª2015 The Autha significant increase in any p53 targets in differentiated
cells. These data identify a specific subset of p53 target
genes that are upregulated in response to CDK1 inhibition
in mESCs.
Of the significantly upregulated p53 targets, RB, TP73,
and WIG1 function in cell-cycle arrest and/or p53 stability
mechanisms, while only NOXA has a predominantly
apoptotic function. NOXA is a BCL2 homology domain 3
(BH3)-only pro-apoptotic member of the BCL2 family
of proteins, which regulate cell survival and cell death
through the intrinsic apoptotic pathway.
Given the strong connection between NOXA and the
intrinsic apoptotic pathway, we chose to investigate
whether NOXA mediates CDK1-inhibitor-induced death
in mESCs. To verify our array results, we examined mRNA
levels of Bbc3 (PUMA) and Pmaip1 (NOXA), in response to
CDK1 inhibitor treatment by quantitative RT-PCR. Consis-
tent with our array results, we observed no change in Bbc3
mRNA levels, while Pmaip1 was significantly upregulated
after purvalanol A treatment inmESCs (Figure S3A). Upregu-
lation of Pmaip1 was not observed in either p53/ mES or
mES-diff cells, indicating that induction of Pmaip1 is p53-
dependent and requires the pluripotent state (Figure S3A).
NOXAprotein levels also increased uponpurvalanol A treat-
ment, which correlated with an increase in p53 protein
levels, in mESCs but not mES-diff cells (Figure 5B). Pretreat-
ment ofmESCswithNOXA-specific siRNAs prior to purvala-
nol A treatment significantly reduced the levels of cell death
(Figure 5C). These results indicate that NOXA is a major
contributor toCDK1-inhibitor-induced cell death inmESCs.
NOXA regulates apoptosis predominately through the
inactivation of myeloid cell leukemia sequence 1 (MCL1),
an anti-apoptotic BCL2 family member (Deng et al.,
2007). Binding of NOXA to MCL1 relieves MCL1’s binding
and repression of pro-apoptotic proteins and leads to the
degradation of MCL1 through the proteasomal pathway
(Nakajima et al., 2014). Whether NOXA or MCL1 regulate
mouse or human ES cell survival has not been established.
Western blot analysis of MCL1 revealed it to be highly ex-
pressed in mESCs compared to mES-diff cells (Figure 5B).
In contrast, other anti-apoptotic BCL2 family members,
BCL2 and BCL-XL, were expressed in mES-diff cells but(C) PARP cleavage after purvalanol A (purv) treatment for the
indicated amount of hours (h) shown by western blot.
(D) Western blot for p53, and phospho-p53 (S18) after treatment
with purvalanol A. Cells were treated with 1 mM doxorubicin (Doxo)
for 4 hr as a positive control.
(E) Western blot for p53 72h after siRNA knockdown of indicated
CDKs and cyclins. Ctrl refers to non-targeting control siRNA.
(F) Western blot for p53 in nuclear and cytosolic fractions after
10 mM purvalanol A (purv). Lamin and b-tubulin represent nuclear
and cytosolic fractions, respectively.
ors
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Figure 5. CDK1 Inhibition Induces Expression of Bcl2 Family Member NOXA and Depletes MCL1 to Induce Cell Death in mESCs
(A) Fold change mRNA expression of p53 transcriptional targets in mES and mES-diff cells after treatment with purvalanol A for 8 hr
(mean ± SEM n = 4 independent experiments). Treated samples were compared to DMSO-treated controls for each cell type. 2(-Dct) of
treated and untreated populations compared using a Student’s t test, *p < 0.05.
(B) Western blot for indicated proteins after 10 mM purvalanol A (purv) treatment for indicated time in hours (h).
(C) Cell viability of mESCs pretreated with siRNA against Noxa after 24-hr treatment with 10 mM purvalanol A (mean ± SEM n = 4 inde-
pendent experiments). Populations compared using a Student’s t test, *p = 0.01. Western blot depicts level of NOXA knockdown achieved
at time of purvalanol A treatment.
(D) Western blot analysis of indicated proteins in mESCs after CDK1 siRNA knockdown. Ctrl refers to non-targeting control siRNA.
(E) Western blot analysis of MCL1 and PARP cleavage after siRNA knockdown of MCL1.
(F) Cell viability after siRNA knockdown of MCL1, normalized to a non-targeting control (mean ± SEM n = 4 independent experiments).
siRNA-treated and control populations compared by a Student’s t tests, *p = 0.0003. NS, not significant.
See also Figure S3could not be detected in mESCs (Figure 5B), suggesting
MCL1 is a predominant regulator of mESC survival.
MCL1 protein levels were significantly decreased in mESCs
upon purvalanol A treatment, correlating with the increase
in NOXA expression (Figure 5B). We confirmed that activa-
tion of the p53-NOXA axis andMCL1 depletion was due to
CDK1 inhibition, and not an off-target effect of smallmole-Stem Ccule CDK inhibitors, using siRNA-mediated knockdown of
CDK1. Consistent with the small molecule studies, CDK1
depletion resulted in increased protein levels of p53 and
NOXA, decreased MCL1, and induction of PARP cleavage
(Figure 5D).
We next used siRNAs to deplete MCL1 in mESCs,
mESC-diff cells, and MEFs (Figure 5E). MCL1 knockdownell Reports j Vol. 4 j 374–389 j March 10, 2015 j ª2015 The Authors 381
in mESCs resulted in significant levels of cell death
(approximately 50%) compared to a non-targeting control
(Figures 5E and 5F). While mES-diff cells exhibited low
levels of cell death in response to transfection reagents,
they did not undergo additional cell death after MCL1
knockdown compared to a non-targeting control (Figures
5E and 5F). MCL1 knockdown also did not induce appre-
ciable cell death in MEFs (Figures 5E and 5F). These results
suggest that MCL1 is critical for mESC survival and there-
fore CDK1 inhibition could selectively kill mESCs though
inactivation of MCL1.
hESCs Are Sensitive to CDK1 Inhibition and Express
High Levels ofMCL1Compared toDifferentiated Cells
Similar to their murine counterparts, hESCs exhibit an
accelerated cell-cycle program with a shortened G1 phase,
characterized by heightened CDK activity and lack of
endogenous CDK inhibitors (Neganova et al., 2009).
Despite these similarities, many fundamental differences
in cell signaling pathways, including expression patterns
of cell-cycle regulatory machinery, have been reported be-
tween hESCs and mESCS (Becker et al., 2006; Schnerch
et al., 2010). To determine if hESCs are also sensitive to
CDK1 inhibition, we treated two independently derived
hESC lines, UCSF4 and aMel1-derived insulin GFP reporter
line (Mel1INS/GFP) (Micallef et al., 2012), with purvalanol A.
Both hESC lines underwent significant cell death after
24 hr of CDK1 inhibitor treatment (Figures 6A and 6B).
We differentiated Mel1INS/GFP hESCs along a pancreatic
progenitor lineage using an established 15-day differentia-
tion protocol. Differentiated insulin-producing cells can be
readily identified because GFP is expressed from the insulin
promoter. This protocol generates a hESC-derived pancre-
atic progenitor cell population with an average of 5% in-
sulin-producing cells (Guo et al., 2013; Schulz et al., 2012).
We did not observe significant cell death when differenti-
atedMel1INS/GFP hESCswere treatedwith purvalanol A (Fig-
ures 6A and 6B). Both undifferentiated and differentiated
Mel1INS/GFP hESCs arrested inG2/M to a similar extent after
purvalanol A treatment, indicating that CDK1 was being
targeted in both cell types (Figure 6C). Furthermore, we
did not see a significant change in the percentage of insu-
lin-expressing cells, by fluorescence-activated cell sorting
(FACS) analysis of GFP expression (Figure 6D), indicating
that CDK1 inhibitor treatment does not affect the differen-
tiated insulin-producing population of cells. Thus, CDK1
inhibition elicits cell death in both mouse and human
undifferentiated ESCs but not cells that have been differen-
tiated, supporting a common dependency on CDK1 in
mouse and human ESCs.
To determine whether CDK1 inhibition induces cell
death in hESCs and mESCs through similar mechanisms,
we assessed protein levels of g-H2AX and p53 after CDK1382 Stem Cell Reports j Vol. 4 j 374–389 j March 10, 2015 j ª2015 The Authinhibitor treatment in hESCs. 24-hr treatment with purva-
lanol A resulted in increased levels of g-H2AX in undiffer-
entiated but not differentiated hESCs (Figure 6B). p53
expression levels were also increased in hESCs after purva-
lanol A treatment (Figure 6B). The increase in p53 protein
was accompanied by a significant increase in expression
of NOXA, both at the mRNA (Figure 6E) and protein level
(Figure 6F). Interestingly, differentiated hESCs also ex-
hibited an increase in p53 levels after purvalanol A treat-
ment, without appreciable cell death (Figure 6B). We did
not, however, observe an increase in NOXA mRNA or pro-
tein levels in differentiated hESCs, despite the increased
p53 expression (Figures 6E and 6F). Thus, CDK1 inhibition
in differentiated hESCs results in increased p53 expression,
without downstream activation of NOXA or subsequent
cell death.
Increased NOXA expression in hESCs after purvalanol A
treatment implicates a change in MCL1 activity as a me-
diator of CDK1-inhibitor-induced death. Western blot
analysis revealed that, similar tomESCs,MCL1 is highly ex-
pressed in hESCs compared to differentiated hESCs (Fig-
ure 6F). Other anti-apoptotic family members, BCL2 and
BCL-XL, were expressed at lower levels in hESCs compared
to differentiated hESCs (Figure 6F), indicating MCL1 as a
predominant anti-apoptotic factor expressed in hESCs. To
determine whether CDK1 inhibition induced cell death
in hESCs through altered MCL1 expression, we examined
total MCL1 protein levels after treatment with purvalanol
A. In contrast to mESCs, we did not see a significant de-
crease in total MCL1 levels in hESCs after purvalanol A
treatment (Figure 6F). NOXA can block MCL1’s ability
to inhibit the pro-apoptotic function of BAX and BAK
without markedly changing MCL1’s abundance (Hauck
et al., 2009). Thus, increased NOXA expression in the pres-
ence of even a modest decrease of MCL1 expression would
be expected to sensitize hESCs for cell death.
In addition to inhibition by NOXA, MCL1 is also regu-
lated by phosphorylation by multiple kinases known to
regulate both its stability and activity (Hauck et al.,
2009). CDK1 has been shown to directly phosphorylate
serine 64 (S64) of human, but not mouse, MCL1 (Kobaya-
shi et al., 2007). Mouse MCL1 contains a glutamic acid
rather than a serine at this residue, which likely functions
as a constitutive phosphomimetic. Phosphorylation of
S64 by CDK1 enhances its anti-apoptotic function of
MCL1 without affecting protein stability (Kobayashi
et al., 2007). Purvalanol A treatment resulted in a decrease
in S64 phosphorylation of MCL1 (Figure 6F). These data
suggest that CDK1 inhibition negatively affects the anti-
apoptotic function of MCL1 in hESCs, both indirectly
through induction of NOXA and directly through loss of
phosphorylation of S64. Furthermore, siRNA knockdown
of MCL1 induced cell death in H9 hESCs, but not humanors
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Figure 6. Small Molecule Inhibition of CDK1 Induces Apoptosis in hESCs
(A) Cell viability after 24-hr treatment with DMSO or purvalanol A (10 mM) (mean ± SEM n = 3 independent experiments). Populations were
compared using a Student’s t test *p < 0.01. NS, not significant.
(B) Western blot analysis of indicated proteins in hESCs and differentiated hESCs (hESC-diff) after purvalanol A treatment for 24 hr.
(C) Effect of purvalanol A on undifferentiated and differentiated hES cell cycle distribution. Percentages of cells in each cell-cycle phase,
mean ± SEM, n = 3 independent experiments.
(D) Percentage of insulin-producing cells as determined with FACS analysis using an insulin-GFP reporter cell line (mean ± SEM n = four
independent experiments).
(E) Relative expression of PMAIP1mRNA after purvalanol A treatment in hESCs and hESC-diff, determined by quantitative PCR (mean ± SEM
n = four independent experiments). Treated samples compared to untreated samples for each cell type independently, using a paired
Student’s t test, *p < 0.05.
(F) Western blot analysis of indicated proteins after purvalanol A treatment for indicated time in hours (h).
(G) Western blot analysis of MCL1 after siRNA knockdown of MCL1.
(H) Cell viability after siRNA knockdown of MCL1, normalized to a non-targeting control (mean ± SEM n = 4 independent experiments).
siRNA-treated and control populations compared by a Student’s t tests, *p = 0.02. NS, not significant.
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embryonic kidney (HEK293) cells, a differentiated cell type
(Figures 6G and 6H), suggesting that MCL1 is critical for
hESC survival. It has recently been shown that hESCs are
highly primed toward apoptosis due to the balance of
pro- and anti-apoptotic proteins, particularly the low
expression of BCL2 (Liu et al., 2013). Our present work
adds to this hypothesis and suggestsMCL1 is a critical regu-
lator of hESC survival. We therefore conclude that high
MCL1 expression sensitizes hESCs to MCL1 deregulation,
and CDK1 inhibition induces apoptosis in hESCs by nega-
tively regulating MCL1 anti-apoptotic function.
CDK1 Inhibition Depletes OCT4-Positive
Undifferentiated Cells and Prevents the Growth
of Stem Cell-Derived Tumors
Our data suggest that pluripotent cells are uniquely sensi-
tive to CDK1 inhibition.We reasoned that CDK1 inhibitors
could selectively deplete residual undifferentiated cells dur-
ing stem cell transplantation, thus reducing the occurrence
of ESC-derived teratomas. We generated a partially differ-
entiated ESC population by treating mESCs with RA for
2 days, resulting in greater than 80% reduction of Oct4
mRNA expression (Figure S2A). Immunofluorescence anal-
ysis revealed a heterogeneous population of cells based on
the expression patterns of OCT4 and Nanog (Figure 7A).
Treatment of partially differentiated mESC populations
with 15 mM purvalanol A for 24 hr significantly reduced
the percentage of OCT4 and Nanog-expressing cells (Fig-
ures 7A and 7B). These results indicate that CDK1 inhi-
bition preferentially depletes pluripotent cells within a
partially differentiated population.
To determine if depletion of OCT4 and Nanog-express-
ing cells would reduce the risk of teratoma formation, we
subcutaneously transplanted into BALB/c Nu/Nu mice
with equal numbers of viable, partially differentiated
mESCs, treated with either 15 mM purvalanol A or DMSO
for 24 hr, and monitored daily for tumor formation. Trans-
plants with DMSO-treated cells resulted in visible tumors
as early as 5 days after transplantation, with 17 of 18
mice developing tumors during the 45-day course of the
experiment (Figure 7C). Mice transplanted with purvala-
nol-A-treated cells exhibited decreased tumor incidence,
with only 3 of 13 mice developing visible tumors (Fig-
ure 7C), suggesting that CDK1 inhibition depletes tumori-
genic cells from a heterogeneous population.
We next investigated if in vivo treatment with CDK in-
hibitors could prevent the formation of stem cell-derived
tumors. We used an alternative CDK inhibitor, dinaciclib,
which has improved pharmacokinetic properties com-
pared to purvalanol A (Parry et al., 2010). Dinaciclib in-
hibits CDK1, 2, 5, and 9 and is currently in clinical trials
against multiple tumor types (Dickson and Schwartz,
2009). Mice were transplanted with viable, partially differ-384 Stem Cell Reports j Vol. 4 j 374–389 j March 10, 2015 j ª2015 The Authentiated mESCs and treated with intraperitoneal (i.p.) in-
jections of dinaciclib or diluent control starting 72 hr after
transplant. A treatment regimen of twice-weekly intraperi-
toneal injections was continued for 4 weeks. Mice in the
control group developed tumors as early as 5 days post-
transplantation, with four of five mice developing tumors
over the course of the 4-week experiment (Figure 7D). In
contrast only one out of seven of the dinaciclib-treated
mice developed a tumor (Figure 7D). Therefore, in vivo
treatment with a CDK1 inhibitor decreases the formation
of stem cell-derived tumors.
Tumors that formed after transplantation with partially
differentiated mESCs grew aggressively, reaching the
ethical endpoint (400 mm2) within 2–3 weeks after detec-
tion. We asked if dinaciclib treatment would attenuate
the growth of established stem cell-derived tumors. We
transplanted mice with partially differentiated mESCs
and allowed tumors to develop. When palpable tumors
formed (range, 50–100 mm2 in volume), we began intra-
peritoneal injections with dinaciclib or diluent control.
Within the control group, tumors continued to grow
rapidly, reaching the ethical endpoint within 2 weeks after
injections began. Dinaciclib-treated mice tumors grew
significantly more slowly, indicating that CDK inhibitors
slow the growth of established stem cell-derived tumors
(Figures 7E and 7F).
The difference in growth rate of treated versus untreated
cells led us to ask if dinaciclib treatment affected tumor
composition. At the end of the 26-day treatment regimen
or when tumors reached the ethical size endpoint, we
collected tumors and stained with hematoxylin and eosin
(H&E). In a blinded analysis, ten fields from each tumor
were characterized based on their percentage composition
of the following categories: necrosis, embryonal carci-
noma, immature teratoma (including primitive epithe-
lium/neuroepithelium and cellular atypical glial tissue),
mature teratoma (including respiratory epithelium, squa-
mous epithelium, and cartilage), and other (including
inflammatory cells and stromal tissue). Tumors from the
control group exhibited tissues derived from all three
germ layers and showed substantial components of embry-
onal carcinoma and immature teratoma (Figure S4). There
was a decrease in the immature teratoma component after
dinaciclib treatment (Figure 7G; Figure S4). Furthermore,
tumors from the dinaciclib-treated group showed an in-
crease in necrotic tissue (Figure 7G; Figure S4A), suggesting
that some stem cell-derived tissues were undergoing cell
death after dinaciclib treatment. Because dinaciclib targets
CDKs 2, 5, and 9 in addition to CDK1, we asked if off-target
effects might contribute to stem cell death. We previously
showed that siRNA knockdown of CDK2 has no effect on
mESC viability (Figure 1C). We found that siRNA knock-
down of CDKs 5 and 9 also had no effect on cell cycle orors
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Figure 7. Treatment with CDK1 Inhibitors Prevents mESC-Driven Tumors In Vivo
(A) OCT4 and Nanog expression in undifferentiated mESCs and after 2 days of treatment with 1 mM retinoic acid (mES 2dRA) ± 15 mm
purvalanol A for 24 hr. Scale bar, 40 mm (left).
(B) Percentage of OCT4-positive (left) and Nanog-positive (right) cells from immunofluorescence experiment in (A) (mean ± SEM n = 3
independent experiments). Populations compared using a Student’s t test, *p < 0.02.
(C) Kaplan-Meier graph showing the percentage of mice that remained teratoma free after subcutaneous transplantation. Significance of
differences in each population determined by the log rank test, p = 0.001.
(D) Kaplan-Meier graph showing the percentage of mice that remained teratoma free after subcutaneous transplantation with partially
differentiated ES cells. Mice received dinaciclib or vehicle treatment. p < 0.05, determined by the log rank test.
(E) Percentage tumor growth in mice injected with dinaciclib (n = 7) versus vehicle (n = 8). Control and treated mice after 14 days of
treatment compared using a Student’s t test *p = 0.0001.
(F) Mouse teratomas after treatment with dinaciclib or vehicle. Scale bars, 10 mm.
(G) Quantification of tumor composition, based on defined categories. Control- (n = 8) and dinaciclib-treated tumors (n = 7) compared
using a Student’s t test, *p < 0.0004.
See also Figure S4.cell viability of mES cells (Figures S4B and S4C). These re-
sults raise the intriguing possibility that CDK1 inhibition
in vivo attenuates tumor growth by selectively killing
poorly differentiated, immature stem cell-derived tumor
components.Stem CDISCUSSION
In this study, we investigate the unique cell-cycle depen-
dencies of mouse and human ES cells. We discovered that
inhibition or depletion of CDK1 or its associated cyclinsell Reports j Vol. 4 j 374–389 j March 10, 2015 j ª2015 The Authors 385
can selectively cause DNA damage and induce apoptosis in
ESCs. In contrast, inhibition or depletion of other cyclins or
CDKs in ESCs failed to induce appreciable cell death. We
find that mouse and human ESCs exhibit increased p53
activity, NOXA induction, MCL1 inactivation, and subse-
quent cell death after CDK1 inhibition. Furthermore, we
show that CDK1 inhibitors can prevent mESC-derived tu-
mors and inhibit the growthof established tumors. These re-
sults demonstrate a unique requirement for CDK1 inmouse
and human ES cells and identify CDK1 as a potential thera-
peutic target to prevent or treat stem cell-derived tumors.
Our findings indicate that theG2/M/G1 transition events
that are regulated by CDK1 activity are the most critical for
the proliferation and survival of ESCs. Depletion of cyclin
D1 or E cyclins and CDK2 did not have appreciable effects
on cell proliferationanddidnot induce cell death (Figure 1).
These results are consistent with the observation that loss
of CDK4/6 or CDK2 can be compensated by CDK1 activity
(Santamarı´a et al., 2007). CDK1 activity, however, is also
critically important for overall genome stability, including
the maintenance of faithful chromosome segregation and
the ability of cellular DNA damage repair to occur through
homologous recombination (Johnson et al., 2011; Keeney
andNeale, 2006; Peterson et al., 2011). Thus, the uniquede-
pendency of ESCs on CDK1 activity may ensure that cells
that have failed appropriate transitions in G2/M/G1, and
are therefore at risk for harboring aberrant genomes, will
be eliminated through apoptosis.
A secondary mechanism to ensure genomic fidelity is
manifested in a switch in the apoptotic program employed
by ESCs. In this study, we discovered a cell-death pathway
involving NOXA and MCL1 that is uniquely activated to
induce cell death in ESC but not differentiated cells. The
apoptotic potential of NOXA overexpression is dependent
on the cellular and genetic context (Ploner et al., 2008).
Compared to other BH3-only proteins, including PUMA,
BIM, or BAD, NOXA exhibits the most limited potential
to bind and sequester anti-apoptotic proteins, binding
almost exclusively to MCL1 (Chen et al., 2005). Therefore,
susceptibility to NOXA-induced cell death is dependent on
MCL1 activity relative to other anti-apoptotic proteins
(Ploner et al., 2008). We find that mouse and human
ESCs highly express MCL1, but not other anti-apoptotic
proteins, such as BCL2 or BCL-XL. In contrast, upon differ-
entiation MCL1 expression decreases, but BCL2 and BCL-
XL expression is induced. Thus, an apparent ‘‘apoptotic
switch’’ occurs as cells transition from pluripotency to a
differentiated state. Consistent with this observation, we
find that both mouse and human ESCs, but not diff-ESCs
are sensitive to MCL1 inhibition (Figures 5 and 7). CDK1
inhibition acts at multiple steps to inactivate MCL1, both
by inducing NOXA, as well as through inhibition of S64
phosphorylation in hESCs.386 Stem Cell Reports j Vol. 4 j 374–389 j March 10, 2015 j ª2015 The AuthA recent study by Liu et al. (2013) demonstrated that the
mitochondria of hESCs are highly primed to undergo DNA
damage-induced apoptosis. Our current study has identi-
fied a unique upstream stimulus via CDK1 inhibition that
selectively induces DNA damage in ESCs but not appre-
ciably in differentiated cells. Taken together, the emerging
picture is one where ESCs, upon inactivation of CDK1,
experience DNA damage that differentiated cells do not
perceive and are also poised to die in response to this
damage.
In this study, we exploit the unique cell cycle of mouse
and human ES cells to induce selective cell killing. We
found that the CDK1 inhibitor purvalanol A effectively
depleted the Nanog and OCT4-expressing cells from a
mixed population of differentiated and undifferentiated
cells. Furthermore, we show that a clinically relevant
CDK inhibitor, dinaciclib, can both prevent the initiation
and inhibit the progression of stem cell-driven tumors
in vivo. Our study identifies critical differences in the path-
ways controlling cellular proliferation and apoptosis of
ESCs versus differentiated cells. ESCs are poised to utilize
a p53-NOXA-MCL1 axis to respond to DNA damage
induced by CDK1 inhibition and undergo cell death.EXPERIMENTAL PROCEDURES
Cell Culture
Mouse embryonic stem cell lines, E14, oct4-GFP E14, p1.2 (p53/),
DGCR8/, and Bax/ Bak/ were maintained on plates coated
with 0.2% gelatin in knockout DMEM (Gibco) supplemented
with 15% FBS, 1 3 nonessential amino acids, 1 3 glutaMAX-1,
100 units/ml penicillin-streptomycin, and 0.1 mM2-mercaptoetha-
nol and recombinant leukemia inhibitory factor. miPS cells were
generated as previously described (Takahashi and Yamanaka,
2006). UCSF4 (NIH registry no. is 0044) and Mel1INS/GFP (Micallef
et al., 2012) human embryonic stem cells were maintained on
non-proliferative MEFs in standard DMEM/F12 medium supple-
mented with 10 ng/ml FGF2. MEFs and HEK293 cells were grown
in DMEM supplemented with 10% FBS and 100 units/ml peni-
cillin-streptomycin. H9 human embryonic stem cells were main-
tained on matrigel coated plates in Essential 8 media (Gibco).
All cell lines were maintained in 5% CO2 at 37C. mESCs were
reverse-transfected, and hESCswere forward-transfected, using Lip-
ofectamine RNAi MAX (Invitrogen), according to manufacturers
instructions. siRNAs and a pool of non-targeting control siRNA
(Dharmacon control #2) were purchased from Dharmacon
(siGENOME SMART pool siRNA; Dharmacon) and used at a con-
centration of 50 nM (cyclins, Noxa and Mcl1) or 100 nM (Cdks).
All human ES cell line experiments were approved by the Univer-
sity of California San Francisco institutional use committee.Protein Preparation and Western Blotting
Cultured cells were harvested into radioimmunoprecipita-
tion assay (RIPA) buffer (50 mM Tris, 150 mM NaCl, 0.5%ors
sodium-deoxycholate, 1% NP-40, 0.1% SDS, 2 mM EDTA [pH 7.5])
containing COMPLETE protease inhibitor cocktail (Roche) and
phosphatase inhibitors (Santa Cruz Biotechnology). Protein con-
centrations were determined by performing DC Protein Assay
(Bio-Rad) using BSA as standard. See Supplemental Information
for antibodies used.
Cell-Cycle and Cell-Death Analysis
Cell viability was determined using a flow-cytometry-based Guava
ViaCount viability assay (Millipore), performed according to the
manufacturer’s instruction. For cell-cycle analysis, cells were fixed
by dropwise addition of ice-cold EtOH and storage at 20C. Fixed
cells were stained with propidium iodide, and samples were
analyzed on a LSRII flow cytometer (BD Biosciences). Cell popu-
lations were gated to exclude doublets. Sub2N levels were de-
termined using FlowJo (Tree Star) analysis software. Univariate
cell-cycle analysis was performed by excluding dead cells and using
the Watson model cell-cycle analysis program provided by FlowJo
analysis software.
EC50 Calculations
The half-maximal response (EC50) was estimated by nonlinear
regression analysis of the concentration-response curves using
GraphPad Prism. Response presented as percentage maximal
response for each cell type. Fisher’s exact test was used to deter-
mine the significance of differences in EC50 values for each cell
type.
Mouse Xenograft Studies
All animal experimentswere approved by theUniversity of Califor-
nia San Francisco institutional animal care and use committee. For
complete description of xenograft studies and all other additional
methods, please see Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures and four figures and can be found with this article on-
line at http://dx.doi.org/10.1016/j.stemcr.2015.01.019.
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